Sessions

*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.


15:00 - 15:03: Introductory note

Tom H. M. Ottenhoff

15:03 - 15:23: TB biomarkers and first results of the CORTIS trial

Thomas Scriba

15:23 - 15:43: BCG vaccination, trained immunity, TB and COVID-19

Reinout van Crevel

15:43 - 16:03: Antibodies as a bridge between the innate and adaptive immune system

Galit Alter

16:03 - 16:22: Live Q&A

*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-01-Inflammatory markers in the cerebrospinal fluid linked to mortality in tuberculous meningitis

Valerie A.C.M. Koeken

16:40 - 16:48: TBS-OA-02-Vaccination with intravenous BCG protects SIV+ macaques from tuberculosis.

Erica Larson

16:48 - 16:56: TBS-OA-03-A pilot study on plasma metabolomic characterization of patents with MDR-TB

Qi Tan

16:56 - 17:04: TBS-OA-04-A 22-gene transcriptomic model predicting individual therapy durations in multidrug-resistant tuberculosis

Jan Heyckendorf

17:04 - 17:12: Live Q&A

*Please scroll down for more information*
In this session recent insights into the host immune response to M. tuberculosis infection will be discussed. The results from a first tuberculosis (TB) biomarker guided clinical trial will be reported and discussed in the context of TB risk and targeted interventions. The role of innate trained immunity will next be reviewed and discussed, including in the context of BCG vaccination. The emerging role of antibodies in TB will be reviewed as well. The three keynote presentations will be followed by the selected abstract presentations and close with an open panel discussion.


17:20 - 17:45: Panel discussion

Thomas Scriba
Reinout van Crevel
Galit Alter
Ann Ginsberg

17:45 - 18:05: Live Q&A

Thomas Scriba
Reinout van Crevel
Galit Alter
Ann Ginsberg

*Please scroll down for more information*
Recent research has suggested that M. tuberculosis can present as more subtle states than just 'latent' infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modelling and economic analyses implications. This session is intended to discuss different implications of the spectrum of tuberculosis infection.

15:00 - 15:03: Introductory note


15:03 - 15:23: Subclinical TB in epidemiological models: What we know, what we don't, and what difference it makes

Emily Kendall

15:23 - 15:43: Bacterial and host determinants of cough aerosol culture-positivity in patients with drug-resistant or drug-susceptible TB

Grant Theron

15:43 - 16:03: Natural history of subclinical tuberculosis tracked by PET/CT and blood biomarkers

Anna Coussens

16:03 - 16:22: Live Q&A

*Please scroll down for more information*
Recent research has suggested that M. tuberculosis can present as more subtle states than just 'latent' infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modelling and economic analyses implications. This session is intended to discuss different implications of the spectrum of tuberculosis infection.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-05-Transcriptomic profile of aerosolized Mycobacterium tuberculosis from patients during the early phase of drug-sensitive anti-tuberculosis treatment

Ambreen Shaikh

16:40 - 16:48: TBS-OA-06-Antigen-specific T cell activation distinguishes between recent and remote tuberculosis infection

Elisa Nemes

16:48 - 16:56: TBS-OA-07-Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease

Jon C. Emery

16:56 - 17:04: TBS-OA-08-Cough-independent production of metabolically active Mycobacterium tuberculosis in bioaerosol

Benjamin Patterson

17:04 - 17:12: Live Q&A

*Please scroll down for more information*
Recent research has suggested that M. tuberculosis can present as more subtle states than just 'latent' infection and active disease. This has relevant diagnostic, preventive, therapeutic, transmission, modelling and economic analyses implications. This session is intended to discuss different implications of the spectrum of tuberculosis infection.

17:20 - 17:45: Round table

Simone Joosten
Rein Houben
Paul Drain

17:45 - 18:05: Live Q&A

Simone Joosten
Rein Houben

*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and, ultimately, undermining elimination strategies. For this reason, understanding the detailed mechanisms of resistance, as well as interactions between the host and different drugs, is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility, notably based on genome sequence data.

15:00 - 15:03: Introductory note


15:03 - 15:23: Sequencing to support DR TB treatment decisions: a new landscape of options

Timothy Rodwell

15:23 - 15:43: From MoR to MoA to new drugs

Thomas Dick

15:43 - 16:03: The role of M. tuberculosis within-host heterogeneity. Can it inform TB patient care?

Maha Farhat

16:03 - 16:22: Live Q&A

*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and ultimately undermines elimination strategies. For this reason, understanding the detailed mechanisms of resistance as well as interactions between the host and different drugs is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility notably based on genome sequence data.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-09-Association of delamanid concentrations with treatment outcomes or drug resistance among patients with MDR-TB.

Daniel S. Graciaa

16:40 - 16:48: TBS-OA-10-High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in Cape Town, South Africa

Brigitta Derendinger

16:48 - 16:56: TBS-OA-11-ncRv0842c, a smallRNA regulating the efflux pump Rv0842 involved in rifampicin tolerance in M. tuberculosis

Paolo Miotto

16:56 - 17:04: TBS-OA-12-Genomic sequence characteristics and the empirical accuracy of short-read sequencing in Mycobacterium tuberculosis

Maximillian Marin

17:04 - 17:12: Live Q&A

*Please scroll down for more information*
Multiple active anti-mycobaterial drugs are required to cure tuberculosis. Monotherapy or treatment with insufficient active drugs accelerates the development of mycobacterial resistance resulting in treatment failures and, ultimately, undermining elimination strategies. For this reason, understanding the detailed mechanisms of resistance, as well as interactions between the host and different drugs, is important as it allows in vivo activity to be predicted. This session aims to discuss recent findings with respect to our understanding of anti-mycobacterial drug resistance and the prediction of susceptibility, notably based on genome sequence data.

17:20 - 17:45: Panel discussion

Maha Farhat
Thomas Dick
Sarah Fortune
Timothy Rodwell

17:45 - 18:05: Live Q&A

Maha Farhat
Thomas Dick
Sarah Fortune
Timothy Rodwell

*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

15:00 - 15:03: Introductory note


15:03 - 15:23: Opportunities and risks: using therapeutic TB vaccines to improve cures and shorten treatment for active disease

Gavin Churchyard

15:23 - 15:43: Single-bacilli response to drug exposure within lesional microenvironments: bug-drug interactions within the granuloma and beyond

Joshua Vasquez

15:43 - 16:03: Diversity of Mycobacterium tuberculosis and clinical outcomes of TB. The challenges posed for optimising HDT for TB

Margarida Saraiva

16:03 - 16:22: Live Q&A